Short Interest in NeuroMetrix, Inc. (NASDAQ:NURO) Rises By 78.6%

NeuroMetrix, Inc. (NASDAQ:NURO) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 2,500 shares, an increase of 78.6% from the February 13th total of 1,400 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily volume of 19,700 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on NeuroMetrix in a research report on Wednesday. They set a “sell” rating for the company.

Institutional Trading of NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. GTS Securities LLC bought a new position in NeuroMetrix, Inc. (NASDAQ:NURO) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned approximately 1.12% of NeuroMetrix at the end of the most recent quarter. 19.40% of the stock is currently owned by hedge funds and other institutional investors.

NeuroMetrix Stock Performance

NASDAQ:NURO remained flat at $4.37 during mid-day trading on Friday. 1,074 shares of the company traded hands, compared to its average volume of 13,926. The stock has a market cap of $8.97 million, a P/E ratio of -0.95 and a beta of 2.15. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $4.73. The company has a 50 day moving average price of $4.26 and a two-hundred day moving average price of $4.10.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.